Form: SCHEDULE 13G

Statement of Beneficial Ownership by Certain Investors






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Checkbox checked   Rule 13d-1(b)
Checkbox not checked   Rule 13d-1(c)
Checkbox not checked   Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G




Comment for Type of Reporting Person:  The amounts reported in boxes 6, 8, and 9 represent 967,740 American Depositary Shares ("Depositary Shares"), each representing five hundred ordinary shares ("Ordinary Shares"), of Kazia Therapeutics Limited (the "Issuer") owned directly by private investment funds managed by ADAR1 Capital Management, LLC ("ADAR1"). Such securities may be deemed to be indirectly beneficially owned by ADAR1. In addition to the Depositary Shares reported above, certain private investment funds managed by ADAR1 hold Series A and Series B warrants exercisable for 1,615,705 Depositary Shares. The Depositary Shares issuable upon exercise of these warrants are excluded from the amounts reported in boxes 6, 8, 9 and 11 because such warrants are subject to 4.99% beneficial ownership limitations determined in relation to the number of Ordinary Shares underlying the Depositary Shares. The percentage in box 11 is based on 15,548,878 Depositary Shares outstanding (representing 7,774,439,234 Ordinary Shares; each Depositary Share represents 500 Ordinary Shares) of the Issuer, as referenced in the Issuer's prospectus supplement dated August 28, 2026, filed pursuant to Rule 424(b)(5) with the Securities and Exchange Commission on August 31, 2026.


SCHEDULE 13G




Comment for Type of Reporting Person:  The amounts reported in boxes 6, 8, and 9 represent 967,740 American Depositary Shares ("Depositary Shares"), each representing five hundred ordinary shares ("Ordinary Shares"), of Kazia Therapeutics Limited (the "Issuer") owned directly by private investment funds managed by ADAR1 Capital Management, LLC ("ADAR1"). Such securities may be deemed to be indirectly beneficially owned by Daniel Schneeberger, the sole manager of ADAR1. In addition to the Depositary Shares reported above, certain private investment funds managed by ADAR1 hold Series A and Series B warrants exercisable for 1,615,705 Depositary Shares. The Depositary Shares issuable upon exercise of these warrants are excluded from the amounts reported in boxes 6, 8, 9 and 11 because such warrants are subject to 4.99% beneficial ownership limitations determined in relation to the number of Ordinary Shares underlying the Depositary Shares. The percentage in box 11 is based on 15,548,878 Depositary Shares outstanding (representing 7,774,439,234 Ordinary Shares; each Depositary Share represents 500 Ordinary Shares) of the Issuer, as referenced in the Issuer's prospectus supplement dated August 28, 2026, filed pursuant to Rule 424(b)(5) with the Securities and Exchange Commission on August 31, 2026.


SCHEDULE 13G



 
ADAR1 Capital Management, LLC
 
Signature:/s/ Daniel Schneeberger
Name/Title:Daniel Schneeberger, Manager
Date:11/16/2026
 
Daniel Schneeberger
 
Signature:/s/ Daniel Schneeberger
Name/Title:Daniel Schneeberger, in his individual capacity
Date:11/16/2026
Exhibit Information

Exhibit A: Joint Filing Agreement